Logo

Epoch Biosciences and Celera Diagnostics Expand Licensing Agreement for Probe Technologies

May 20, 2004

NEW YORK, May 20 (GenomeWeb News) - Epoch Biosciences has expanded its licensing agreement with Celera Diagnostics for two of its probe technologies, Epoch said today.

 

The amended agreement expands Celera's rights to include Epoch's minor groove binder technology, MGB, and its quencher technology, Dark Quencher, into selected infectious disease products.

 

Epoch first licensed the technology to Celera in January.

Breaking News
The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.